Clinical trial
Exenatide Versus Glimepiride in Patients With Type 2 Diabetes
NCT00359762 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00359762 |
|---|---|
| Title | Exenatide Versus Glimepiride in Patients With Type 2 Diabetes |
| Official title | Long Term Treatment With Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Pretreated With Metformin (EUREXA: European Exenatide Study) |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | exenatide, glimepiride |
| Enrollment | 1,029 |
| Start date | Sep 1, 2006 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Aug 2, 2006 |
| Last update posted | Sep 15, 2015 |
| Countries | Austria, Czechia, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Mexico, Poland, Spain and 2 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: